Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Britain says it has offered COVID-19 vaccine to all over-50s

Published 12/04/2021, 22:48
Updated 12/04/2021, 22:50
© Reuters. COVID-19 vaccinations in Blackburn

By Alistair Smout

LONDON (Reuters) - Britain on Monday said it had offered all over-50s a first dose of COVID-19 vaccine, hitting a target to offer injections to all people in its nine highest priority groups by April 15.

Britain has seen one of the world's quickest vaccine rollouts, behind only Israel in the proportion of its population receiving at least one dose of a COVID-19 shot.

The government said it had offered at least one shot to priority cohorts 1 to 9, which include all adults over 50, the clinically vulnerable, and health and social care workers, ahead of Thursday's deadline.

"We have now passed another hugely significant milestone in our vaccine programme by offering jabs to everyone in the nine highest risk groups," Prime Minister Boris Johnson said in a statement.

"We will now move forward with completing essential second doses and making progress towards our target of offering all adults a vaccine by the end of July."

The success of the vaccine programme has underpinned Johnson's roadmap out of lockdown, which on Monday saw all shops and outdoor hospitality settings in England reopen.

But Britain has slowed down the pace of first doses, to ensure people in high-priority groups receive a second dose despite lower vaccine supplies in April than March.

Johnson's office said that the government remained on track to offer all adults a shot by July 31. People in their late 40s are expected to be the next to be invited for shots, though a final decision has not been made, his office said.

The Joint Committee on Vaccination and Immunisation (JCVI) has previously said that it expects to continue an age-based approach to the rollout, rather than prioritising people based on occupation or other risk factors.

© Reuters. COVID-19 vaccinations in Blackburn

Last week the JCVI also said it advised alternatives to AstraZeneca (NASDAQ:AZN)'s vaccine for those under-30, given a very rare possible side effect of blood clots and the age group's low risk from COVID-19.

Latest comments

quite amazing how the government and health care system has accomplished this. All those involved should be congratulated.I'm sure there will be some who want to belittle this accomplishment, but it's about time people stopped the criticism and for once applauded the succes
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.